2 days Ago By ABMN Staff
ProKidney Corp. ( NASDAQ:PROK – Get Free Report ) gapped up before the market opened on Tuesday . The stock had previously closed at $1.
75, but opened at $1.79. ProKidney shares last traded at $1.
75, with a volume of 18,913 shares trading hands. Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports on the stock. Guggenheim started coverage on shares of ProKidney in a research report on Tuesday, September 10th.
They issued a “buy” rating and a $6.00 target price on the stock. JPMorgan Chase & Co.
began coverage on shares of ProKidney in a report on Monday, September 30th. They issued a “neutral” rating on the stock. Finally, Bank of America dropped their price objective on ProKidney from $4.
00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock.
According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.50. Read Our Latest Report on ProKidney ProKidney Trading Down 3.
2 % ProKidney ( NASDAQ:PROK – Get Free Report ) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, meeting analysts’ consensus estimates of ($0.
14). On average, equities analysts predict that ProKidney Corp. will post -0.
57 earnings per share for the current fiscal year. Institutional Investors Weigh In On ProKidney A number of large investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in ProKidney during the 3rd quarter worth approximately $41,000.
Intech Investment Management LLC acquired a new position in shares of ProKidney during the third quarter worth $46,000. AQR Capital Management LLC acquired a new position in shares of ProKidney during the second quarter worth $50,000. The Manufacturers Life Insurance Company purchased a new position in shares of ProKidney in the second quarter valued at $60,000.
Finally, Castleview Partners LLC acquired a new stake in ProKidney during the 3rd quarter valued at $63,000. Institutional investors and hedge funds own 51.59% of the company’s stock.
About ProKidney ( Get Free Report ) ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Further Reading Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter ..
